- Ondansetron is a selective 5-HT3 receptor antagonist. It may affect
serotonin receptors of the peripherally on vagal nerve terminals and
centrally in the chemoreceptor trigger zone of the area postrema.
- A second study evaluated use of oral ondansetron to improve success
of ORT in pediatric patients with acute gastroenteritis. It showed a
reduction in the median number of further episodes of emesis, but no
significant cessation of emesis.3
- Unless the diagnosis of gastroenteritis is highly likely, cessation
of emesis may delay actual diagnosis, and mask actual diagnosis.
- Good side effect profile of ondansetron with no difference compared
to control group. Side effects include headache, diarrhea, constipation,
fever. Low cost of medication compared to hospital admission ($26 per
dose of ondansetron compared to $1900 per admission).
- Reeves JJ, Shannon MW, Fleisher GR. Ondansetron decreases vomiting
associated with acute gastroenteritis: a randomized, controlled trial.
Pediatrics. 2002; 109:e62.
- American Academy of Pediatrics, Subcommittee on Acute Gastroenteritis.
Practice parameter: the management of acute gastroenteritis in young
children. Pediatrics. 1996; 97:424-35.
- Ramsook C, Sahagun-Carreon I, Kozinetz CA, Moro-Sutherland D. A randomized
clinical trial comparing oral ondansetron with placebo in children with
vomiting from acute gastroenteritis. Annals of Emergency Medicine.